Neoprobe signs Cardinal for Lymphoseek sales

Gamma camera probe developer Neoprobe of Dublin, OH, has signed a term sheet covering distribution of its Lymphoseek radiopharmaceutical by healthcare products firm Cardinal Health, also of Dublin.

Cardinal would receive exclusive rights to market and distribute Lymphoseek in the U.S. through its network of 150 nuclear pharmacies. Details of the term sheet are confidential until a definitive agreement has been signed, according to Neoprobe.

Lymphoseek is a lymphatic mapping agent that's labeled with technetium-99m DTPA-mannosyl-dextran, and is designed to be used with handheld gamma detection devices in sentinel lymph node biopsy procedures. Neoprobe is conducting clinical trials of the agent in preparation for a regulatory submission to the U.S. Food and Drug Administration.

By staff writers
July 13, 2007

Related Reading

Neoprobe Lymphoseek trial progresses, June 21, 2007

Neoprobe's Q1 sales slip, loss edges up, May 1, 2007

Neoprobe Lymphoseek trial moves forward, March 5, 2007

Cardinal Health debuts PET, PET/CT database, May 25, 2007

Cardinal makes management moves, February 20, 2007

Cardinal joins Dossia initiative, February 2, 2007

Copyright © 2007

Page 1 of 436
Next Page